AMG-479 (Not yet branded)
Other Medications
Description
AMG-479 is an anti-IGF-1R (insulin-like growth factor-1 receptor) monoclonal antibody designed to block IGF-1R signaling pathways that promote cancer cell growth and survival. In colorectal cancer treatment, it has been evaluated in combination with standard chemotherapy regimens like FOLFIRI, particularly for patients with KRAS-mutant metastatic disease. The drug targets a pathway involved in tumor progression and metastasis in various solid tumors including colorectal carcinoma.
Mechanism of Action
AMG-479 binds specifically to the insulin-like growth factor-1 receptor (IGF-1R) on cancer cells, preventing IGF-1 and IGF-2 from activating this receptor. By blocking IGF-1R signaling, the antibody inhibits downstream pathways including PI3K/AKT and MAPK that promote cancer cell proliferation, survival, and resistance to therapy.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.